Does ERG Expression Predict Docetaxel Benefit in Prostate Cancer?
Tumor expression of the oncogene ERG might predict patient benefit from adding docetaxel to androgen deprivation therapy (ADT), according to... Read More
Tumor expression of the oncogene ERG might predict patient benefit from adding docetaxel to androgen deprivation therapy (ADT), according to... Read More
At this year’s American Society of Clinical Oncology (ASCO) Annual meeting, Alicia K. Morgans, MD, assistant professor of medicine in... Read More
Molecular subtyping of prostate cancer into three categories—luminal A, luminal B, and basal—identifies differences in prognosis and response to treatment,... Read More
Combined urinary testing for PCA3 and TMPRSS2:ERG (T2:ERG) RNA can help avoid unnecessary biopsies while maintaining ability to detect aggressive... Read More
Active surveillance can yield excellent results in carefully selected younger men with prostate cancer, according to a new study. A... Read More
The addition of custirsen to docetaxel and prednisone failed to improve overall survival among patients with metastatic castration-resistant prostate cancer... Read More
Men who receive testosterone replacement therapy (TRT) had an increased rate of favorable-risk prostate cancer compared to those who did... Read More
“Liquid biopsy” analyses of circulating tumor DNA (ctDNA) from blood samples potentially reveal prognostic information about metastatic castration-resistant prostate cancer... Read More
Vascular-targeted photodynamic therapy with padeliporfin was significantly better than active surveillance over a 2-year period in men with low-risk localized... Read More
Long-term follow-up of the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial (PLCO) confirmed earlier results showing no reduction in... Read More